NoneExploration and evaluation of strategic alternatives continue WESTPORT, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. ("Portage” or the "Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today reported its financial results for the fiscal quarter ended September 30, 2024. "We are continuing to explore multiple strategic alternatives to further unlock shareholder value. These may include finding a partner for one or more of our assets, a sale of our company, a merger, restructurings (both in and out of court), a company wind down, further financing efforts, or other strategic actions,” said Dr. Ian Walters, Chief Executive Officer and Chairman of Portage. "The ADPORT-601 trial is paused for further patient accrual pending additional financial resources, and we are analyzing the data. We also continue our collaborations with numerous experts to further understand the biology and utility of our product candidates,” continued Dr. Walters. Financial Results for the Quarter Ended September 30, 2024 The Company incurred a net loss of approximately $1.4 million during the three months ended September 30, 2024 (the "Fiscal 2025 Quarter”), compared to a net loss of approximately $5.2 million during the three months ended September 30, 2023 (the "Fiscal 2024 Quarter”), representing a $3.8 million decrease quarter-over-quarter. Operating expenses, including research and development ("R&D”) costs and general and administrative ("G&A”) expenses, were $1.6 million in the Fiscal 2025 Quarter, down from $5.9 million in the Fiscal 2024 Quarter, a decrease of $4.3 million, as detailed below. R&D costs decreased by approximately $3.5 million, or approximately 83%, from approximately $4.2 million in the Fiscal 2024 Quarter to approximately $0.7 million in the Fiscal 2025 Quarter. The decrease was primarily attributable to the winding down of clinical trial costs (principally CRO-related), which decreased by approximately $1.6 million, from $2.0 million in the Fiscal 2024 Quarter to $0.4 million in the Fiscal 2025 Quarter, as activities ramped down throughout the period since we made the decision to pause enrollment in our sponsored clinical trials in the third and fourth quarters of Fiscal 2024. Manufacturing-related costs decreased by $0.9 million, from $1.0 million in the Fiscal 2024 Quarter to $0.029 million in the Fiscal 2025 Quarter. These decreases reflect the winding down of clinical activity and manufacturing-related costs resulting from our decision to discontinue our sponsored clinical trial for the iNKT program and pause further patient accrual to our sponsored adenosine program. R&D non-cash share-based compensation expense decreased from $0.4 million in the Fiscal 2024 Quarter to nil in the Fiscal 2025 Quarter. Payroll-related expenses decreased by $0.1 million, from $0.37 million in the Fiscal 2024 Quarter to $0.24 million in the Fiscal 2025 Quarter, due to the resignation of two employees in January 2024. Additionally, consulting fees decreased by approximately $0.2 million from $0.25 million in the Fiscal 2024 Quarter to $0.03 million in the Fiscal 2025 Quarter, to reflect the decrease in activity period-over-period. Finally, licensing fees decreased by approximately $0.1 million due to licensing fees paid to the licensor of certain intellectual property utilized in the iNKT clinical trial in Fiscal 2024 Quarter compared to nil in Fiscal 2025 Quarter as the iNKT clinical trial was discontinued in the latter half of Fiscal 2024. G&A expenses decreased by approximately $0.8 million, or approximately 48%, from approximately $1.7 million in the Fiscal 2024 Quarter to approximately $0.9 million in the Fiscal 2025 Quarter. Professional fees decreased by $0.4 million, from $0.8 million in the Fiscal 2024 Quarter to $0.4 million in the Fiscal 2025 Quarter. Payroll-related expenses decreased by $0.1 million from $0.2 million in the Fiscal 2024 Quarter to $0.1 million in the Fiscal 2025 Quarter. The decrease in professional fees and payroll-related expenses is due to the accrual of the monthly fees and payments for the entire second quarter in the first quarter for a consultant and employee in connection with certain Retention Agreements entered into on July 22, 2024. Additionally, G&A non-cash share-based compensation expense decreased by $0.2 million due to the continued vesting of stock options, partially offset by recording all share-based compensation expense as G&A expenses as the result of the discontinuation of the iNKT trial and the pause of further patient accrual in the adenosine program. Finally, directors' fees decreased by $0.1 million in the Fiscal 2025 Quarter, compared to the Fiscal 2024 Quarter, as all directors, except for two directors who resigned in April 2024, waived their fees in the Fiscal 2025 Quarter. The primary reasons for the quarter-over-quarter differences in the Company's pre-tax items of income and expense were the $0.9 million net gain from the settlement and release of obligations and liabilities under the Master Services Agreement between iOx and Parexel partially offset to some extent by the $0.7 million non-cash loss from the change in the fair value of certain warrants accounted for as liabilities, issued in connection with a private placement offering in October 2023, both in the Fiscal 2025 Quarter, and a non-cash loss from the increase in the fair value of the deferred purchase price payable to the former Tarus shareholders and the deferred obligation for the iOx milestone, totaling $0.1 million, in the Fiscal 2024 Quarter. As of September 30, 2024, the Company had cash and cash equivalents of approximately $1.8 million and total current liabilities of approximately $0.9 million. About Portage Biotech Inc. Portage is a clinical-stage immuno-oncology company with a portfolio of multi-targeted therapies to extend survival and significantly improve the lives of patients with cancer. The Company has made the decision to discontinue its sponsored trial for its the invariant natural killer T-cell (iNKT) program and pause further patient accrual to its sponsored adenosine trial program (ADPORT-601 trial) for its potentially best-in-class adenosine antagonists PORT-6 (adenosine 2A inhibitor) and PORT-7 (adenosine 2B inhibitor). The Company is exploring strategic alternatives, which may include finding a partner for one or more of its assets, a sale of the company, a merger, restructurings, both in and out of court, a company wind down, further financing efforts or other strategic actions. For more information, please visit www.portagebiotech.com or find us on LinkedIn at Portage Biotech Inc. Forward-Looking Statements All statements in this news release, other than statements of historical facts, including without limitation, statements regarding about the Company's information that are forward-looking in nature and, business strategy, plans and objectives of management for future operations and those statements preceded by, followed by or that otherwise include the words "believe," "expects," "anticipates," "intends," "estimates," "will,” "may,” "plan,” "potential,” "continue,” or similar expressions or variations on such expressions are forward-looking statements. For example, statements regarding the Company's plans to continue exploring strategic alternatives, which may include finding a partner for one or more of its assets, a sale of the company, a merger, restructurings (both in and out of court), a company wind down, further financing efforts, or other strategic actions, the Company's expectation to replace one patient in the ADPORT-601 trial, and the Company's plans to continue its collaborations with numerous experts to further understand the biology and utility of its product candidates are forward-looking statements. As a result, forward-looking statements are subject to certain risks and uncertainties, including, but are not limited to: the Company's plans and ability to develop and commercialize product candidates and the timing of these development programs; the Company's clinical development of its product candidates, including the results of current and future clinical trials; the benefits and risks of the Company's product candidates as compared to others; the Company's maintenance and establishment of intellectual property rights in its product candidates; the Company's ability to obtain financing in the future to cover its operational costs and progress its plans for clinical development, its estimates regarding its capital requirements, and its ability to continue as a going concern; the Company's estimates of future revenues and profitability; the Company's estimates of the size of the potential markets for its product candidates; its selection and licensing of product candidates; and other factors set forth in "Item 3 - Key Information-Risk Factors” in the Company's Annual Report on Form 20-F for the year ended March 31, 2024 2024 and "Business Environment - Risk Factors” in the Company's Management's Discussion and Analysis for the Three and Six Months ended September 30, 2024 filed as Exhibit 99.2 to the Company's Form 6-K. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from these forward-looking statements. The forward- looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law. FOR MORE INFORMATION, PLEASE CONTACT: Investor Relations: [email protected] Media Relations: [email protected] ---tables to follow--- PORTAGE BIOTECH INC. Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (U.S. Dollars in thousands, except per share amounts) (Unaudited) September 30, September 30, Tarus and deferred obligation - iOx milestone ) ) PORTAGE BIOTECH INC. Condensed Consolidated Interim Statements of Financial Position (U.S. Dollars in thousands) (Unaudited) 2024 2024

EAST RUTHERFORD, N.J. (AP) — With tears occasionally welling in his eyes, Daniel Jones disagreed on Thursday with the New York Giants' decision to bench him earlier this week and perhaps end his five-plus tenure as the team's quarterback. The 27-year-old Jones said he gave the team everything he had after being taken sixth overall in the 2019 draft and he believes he still has a future in the NFL. He held himself accountable for the Giants making the playoffs once in his tenure as the starter. The Duke product took over early in his rookie season when then-coach Pat Shurmur benched two-time Super Bowl MVP Eli Manning, who was near the end of his career. Coach Brian Daboll benched Jones on Monday after the Giants (2-8) returned to practice following a bye week and 20-17 overtime loss to Carolina in Germany. Tommy DeVito will start Sunday against the Tampa Bay Buccaneers, with Daboll hoping he can spark the team. “Definitely not happy about it," said Jones, who read a 90-second statement before taking questions from reporters. “Yeah, not what you want to hear. So, yeah, all those emotions you have. But at the end of the day, this is football. We’re in a business where your expected to get results and we weren’t doing it.” Wearing his no-contact red jersey with a faded No. 8, Jones indicated the Giants offered him the opportunity to walk away from the team with seven games left in the season. He said he is considering it, but he also wanted to stay and help DeVito get ready this week. It is unlikely the Giants are going to let him play again. He has two years left on a four-year, $160 million contract. Next season includes a $23 million guarantee that will kick in if he is hurt and is not ready to start the 2025 season. Since being benched, Jones is barely getting any snaps, with most of them being taken by DeVito and backup Drew Lock. “I got the injury guarantee," Jones said of his lack of work. Asked if he would have waived the guarantee, Jones said general manager Joe Schoen and his agent, Brian Murphy, discussed the issue but that was it. Jones spoke for almost 11 minutes. He got emotional when told receiver Darius Slayton and defensive tackle Dexter Lawrence both referred to him as still the best quarterback on the team. All three were drafted in 2019. Jones called the Giants a first-class organization, cherished the relationships he has and thanked his teammates, coaches and staff. “There have been some great times. But of course, we all wish there had been more of those,” Jones said. “I take full responsibility for my part in not bringing more wins. No one wanted to win more games worse than me. I gave everything I had on the field and in my preparation.” Jones called the 2024 season disappointing and took responsibility. “The idea to change something happens, and I understand. I love the game,” Jones said. “I love being part of a team. I’m excited for the next opportunity. I know that there’s a lot of good football in front of me.” AP NFL: https://apnews.com/hub/nflStock market today: Wall Street hits records despite tariff talk

Afraid of losing the U.S.-Canada trade pact, Mexico alters its laws and removes Chinese partsGabby Logan is forced to apologise to Amazon Prime viewers as pundit swears during the broadcaster's live Champions League coverage Amazon were broadcasting coverage of Man City vs Feyenoord in competition One pundit swore during their analysis before Logan jumped in to apologise Liverpool correspondent LEWIS STEELE tells all on bombshell chat with Mo Salah - LISTEN NOW to It's All Kicking Off! New episodes every Monday and Thursday By LEWIS BROWNING Published: 23:55 GMT, 26 November 2024 | Updated: 23:55 GMT, 26 November 2024 e-mail View comments Amazon Prime presenter Gabby Logan was forced to apologise to viewers after a pundit swore live on air. The broadcaster picked up the rights to the coverage of Manchester City 's Champions League game against Feyenoord on Tuesday, which finished 3-3 as City collapsed late on. In what had appeared to be a routine victory for the Premier League champions, three goals in the last 15 minutes of the match turned the game on its head, with City dropping yet more points in their dire run of form . After the game, the pundits on Amazon were discussing the game and were trying to put their fingers on the reason for their struggles. Alan Shearer picked out one incident , which was a quick free-kick in the dying embers. But eyebrows were raised when Josephine Henning took to the microphone to give her analysis. The former Arsenal defender swore, and appeared to realise her error right away as she looked towards Logan. The presenter wasted no time in apologising, and appeared unimpressed as she did so to viewers of the channel. Gabby Logan was forced to apologise to Amazon Prime viewers after a pundit swore during live Champions League coverage Amazon were in Manchester to broadcast Manchester City's game against Feyenoord Josephine Henning raised eyebrows when she described City's performance as 's***' City have now failed to win in six matches after throwing away a 3-0 lead with 15 minutes left 'I'm talking about if you want to accept that the situation is s***,' Henning said. 'Gabby is looking at me like "Oh my god she said this!".' 'It is the worst. In the second half, they looked afraid. I could see the fear. You have to accept it but then you have to face it brutally.' Logan swiftly added: 'I'm just looking at the time it's 10:20pm. I do apologise.' Social media users didn't seem too fussed, however, with one fan taking to X to write: 'I'll say it again. Champions League coverage on Prime Video Sport is next level. 'Just for Josie Henning calling it as it it. When it's s***, people should be angrier. Love it!' Read More Pep bears the scars of Man City's late collapse as he's left with cut nose and red marks on his head Pep Guardiola 's side had lost their last five matches - including 4-1 against Sporting Lisbon last time out in Europe - and had hope to get back to winning ways before a difficult trip to Anfield to face Liverpool in the Premier League this weekend. The result leaves them down in 15th in the Champions League table, two points short of the top eight and having played one more game than half of the teams in the competition. City have now conceded 17 goals in their last six games - a run which has seen them lose five games and win just once. That includes a 4-0 defeat by Tottenham at the weekend which saw them concede chances at will, while they also shipped four to Sporting, three on Tuesday and two on three occasions. Champions League Gabby Logan Alan Shearer Share or comment on this article: Gabby Logan is forced to apologise to Amazon Prime viewers as pundit swears during the broadcaster's live Champions League coverage e-mail Add comment

Lions place Ennis Rakestraw Jr. on IR, activate Emmanuel Moseley

Lions place Ennis Rakestraw Jr. on IR, activate Emmanuel MoseleyPortage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Mayfield throws 5 TD passes and Bucs keep playoff, NFC South hopes alive with 48-14 rout of Panthers

Jimmy Carter: Many evolutions for a centenarian ‘citizen of the world’

Crackdown to drive crooked cabbies out of the industrySANTA CLARA, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor company, today announced financial results for its third quarter of fiscal year 2025 ended October 31, 2024. Total cash, cash equivalents and marketable debt securities on hand at the end of the third quarter of fiscal 2025 was $226.5 million, compared with $219.8 million at the end of the prior quarter and $222.3 million at the end of the same quarter a year ago. "Company specific factors are more than offsetting broad market weakness, and we are reporting 30% sequential revenue growth in fiscal Q3, above the high-end of our guidance range, with strength led again by our customers' new products, especially those incorporating our higher priced AI inference processors. Edge AI revenue represented about 70% of our total revenue, establishing a new record level, and this momentum is expected to enable growth in both our IoT and Auto markets in F2025 and F2026,” said Fermi Wang, President and CEO. "With the anticipated revenue growth, we intend to drive positive operating leverage and build upon our 15 consecutive fiscal years of positive free-cash-flow.” Quarterly Conference Call Ambarella plans to hold a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time today with Fermi Wang, President and Chief Executive Officer, and John Young, Chief Financial Officer, to discuss the third quarter of fiscal year 2025 results. A live and archived webcast of the call will be available on Ambarella's website at http://www.ambarella.com/ for up to 30 days after the call. About Ambarella Ambarella's products are used in a wide variety of human vision and edge AI applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver/cabin monitoring, autonomous driving and robotics applications. Ambarella's low-power systems-on-chip (SoCs) offer high-resolution video compression, advanced image and radar processing, and powerful deep neural network processing to enable intelligent perception, fusion and planning. For more information, please visit www.ambarella.com . "Safe harbor" statement under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking statements that are not historical facts and often can be identified by terms such as "outlook,” "projected,” "intends,” "will,” "estimates,” "anticipates,” "expects,” "believes,” "could,” "should,” or similar expressions, including the guidance for the fourth quarter of fiscal year 2025 ending January 31, 2025, and the comments of our CEO relating to our expectation of future revenue growth, customer demand for our edge AI inference products, the growth potential of our new products, and our ability to generate positive free-cash flow in future periods. The achievement or success of the matters covered by such forward-looking statements involves risks, uncertainties and assumptions. Our actual results could differ materially from those predicted or implied and reported results should not be considered as an indication of our future performance. The risks and uncertainties referred to above include, but are not limited to, global economic and political conditions, including possible trade tariffs and restrictions; revenue being generated from new customers or design wins, neither of which is assured; the commercial success of our customers' products; our customers' ability to manage their inventory requirements; our growth strategy; our ability to anticipate future market demands and future needs of our customers, particularly for AI inference applications; our ability to introduce, and to generate revenue from, new and enhanced solutions; our ability to develop, and to generate revenue from, new advanced technologies, such as computer vision, AI functionality and advanced networks, including vision-language models and GenAI; our ability to retain and expand customer relationships and to achieve design wins; the expansion of our current markets and our ability to successfully enter new markets, such as the OEM automotive and robotics markets; anticipated trends and challenges, including competition, in the markets in which we operate; risks associated with global health conditions and associated risk mitigation measures; our ability to effectively manage growth; our ability to retain key employees; and the potential for intellectual property disputes or other litigation. Further information on these and other factors that could affect our financial results is included in the company's Annual Report on Form 10-K for our 2024 fiscal year, which is on file with the Securities and Exchange Commission. Additional information will also be set forth in the company's quarterly reports on Form 10-Q, annual reports on Form 10-K and other filings the company makes with the Securities and Exchange Commission from time to time, copies of which may be obtained by visiting the Investor Relations portion of our web site at www.ambarella.com or the SEC's web site at www.sec.gov . Undue reliance should not be placed on the forward-looking statements in this release, which are based on information available to us on the date hereof. The results we report in our Quarterly Report on Form 10-Q for the third fiscal quarter ended October 31, 2024 could differ from the preliminary results announced in this press release. Ambarella assumes no obligation and does not intend to update the forward-looking statements made in this press release, except as required by law. Non-GAAP Financial Measures The company has provided in this release non-GAAP financial information, including non-GAAP gross margin, net income (loss), and earnings (losses) per share, as a supplement to the condensed consolidated financial statements, which are prepared in accordance with generally accepted accounting principles ("GAAP"). Management uses these non-GAAP financial measures internally in analyzing the company's financial results to assess operational performance and liquidity. The company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning, forecasting and analyzing future periods. Further, the company believes these non-GAAP financial measures are useful to investors because they allow for greater transparency with respect to key financial metrics that the company uses in making operating decisions and because the company believes that investors and analysts use them to help assess the health of its business and for comparison to other companies. Non-GAAP results are presented for supplemental informational purposes only for understanding the company's operating results. The non-GAAP information should not be considered a substitute for financial information presented in accordance with GAAP, and may be different from non-GAAP measures used by other companies. With respect to its financial results for the third quarter of fiscal year 2025, the company has provided below reconciliations of its non-GAAP financial measures to its most directly comparable GAAP financial measures. With respect to the company's expectations for the fourth quarter of fiscal year 2025, a reconciliation of non-GAAP gross margin and non-GAAP operating expenses guidance to the closest corresponding GAAP measure is not available without unreasonable efforts on a forward-looking basis due to the high variability and low visibility with respect to the charges excluded from these non-GAAP measures. We expect the variability of the above charges to have a significant, and potentially unpredictable, impact on our future GAAP financial results.

Joe Depa named as EY Global Chief Innovation Officer to lead its global innovation strategyEbonkoli 0-0 0-0 0, Diallo 1-1 0-0 2, Grady 4-7 5-9 16, Petty 7-15 2-4 18, Faas 3-7 0-2 7, Kopp 4-11 9-10 20, Ijeh 0-0 0-0 0, Nyeri 0-3 1-2 1, Hall 0-1 0-0 0, Ammons 0-0 0-0 0, Gob 0-0 1-2 1. Totals 19-45 18-29 65. Adewale 1-1 0-1 2, Klaczek 2-4 1-1 7, Joshua 3-9 1-2 7, Langford 7-8 2-4 16, Marshall 6-16 4-6 18, Neely 2-4 6-7 10, Briggs 1-3 0-0 2, Reddish 1-3 2-2 5, Strand 0-0 0-0 0, Taylor 0-0 0-0 0. Totals 23-48 16-23 67. Halftime_Albany (NY) 34-31. 3-Point Goals_UMKC 9-27 (Grady 3-5, Kopp 3-7, Petty 2-8, Faas 1-4, Hall 0-1, Nyeri 0-2), Albany (NY) 5-19 (Klaczek 2-4, Marshall 2-8, Reddish 1-3, Briggs 0-2, Joshua 0-2). Rebounds_UMKC 35 (Ebonkoli 8), Albany (NY) 16 (Langford 6). Assists_UMKC 14 (Diallo, Kopp 4), Albany (NY) 11 (Joshua, Neely 3). Total Fouls_UMKC 19, Albany (NY) 22. A_100 (12,000).

Alex DanielNone

Suder scores 16 as Miami (Ohio) downs Mercer 75-72Three acres of parsnip (left), two acres of long red mangold (right) and two acres of carrot (far right) being raised for seed at the Moa Seed farm, near Alexandra. — Otago Witness, 3.2.1925 A great deal of careful and painstaking work has been undertaken in the course of the few years that have elapsed since operations were commenced, and sufficient progress has been made to demonstrate clearly that pure seed with a very high percentage of germination can be raised in the dominion, and that the time will probably come when imported seeds will be displaced to a considerable extent by products grown in New Zealand. Up to the present the quality of the seed has been entirely satisfactory, and no trouble has been experienced in disposing of the output. The only drawback is the cost of production, this being principally due to the high price paid for labour. Seeds of the following varieties are now being raised: mangolds, carrots, beetroot, onions, parsnips, potatoes, sweet peas, clovers, lucerne and various grasses. British radio amateur talks to ODT Mr C.W. Goyder, who has been communicating with New Zealand by wireless during the past few days, is about 20 years of age. His experiments started before he left the Mill Hill School, near Hendon, North London, and he was responsible for setting up a transmitter some months ago by means of which he was one of the first amateurs to get into communication with other amateurs in the United States. He received a great amount of publicity on that occasion, but he is naturally prouder of this last achievement than of the previous one, as he now has, as it were, no more worlds to conquer. The set he used to get in touch with Mr Bell, of Waihemo, was another he had assembled in one of the rooms of the science laboratory at Mill Hill School. Mr Goyder lives at Mill Hill, and he has been in the habit of getting up in the morning an hour or two before dawn and conducting his experiments. It was when Mr Goyder was trying to connect with America that he got into touch with New Zealand. It was quite a surprise probably to the operators at both ends. Mr E.J. Symonds. of Gerrard’s Cross was really the first British experimenter to hear a New Zealand station. This was on Thursday morning. He was also the first to have his own Morse code messages heard in New Zealand the next morning. Mr Goyder, working the Mill Hill School set, then established the two-way communication on the Saturday morning. He repeated his performance on Sunday. Other amateurs tuned up to his wave length on Sunday and attempted to call New Zealand and, yesterday morning, Mr Goyder was again in communication with Mr Bell and sent a message of thanks for Mr Massey's congratulations. — by ODT London correspondent Hacking the packing knack When you are packing, heavy things such as shoes should be put at the bottom of the box or suitcase, and the corners filled up with underwear, stockings, and odds and ends not spoiled by crushing. Fasten skirts at the band, allow the folds to fall evenly, and fold across as few times as possible with tissue paper between. Do not turn any garment inside out. Put best blouses and frocks on the top. Tie a piece of old kid glove over the corks and stoppers of bottles, and seal the string, and there is no fear of the contents escaping. — ODT , 9.12.1924 ( Compiled by Peter Dowden )Zhang Anda fired his third career 147 and Stuart Bingham dredged up an improbable 6-5 win over Mark Williams amid “unplayable” accusations on an incident-packed day at the UK Snooker Championship in York. Zhang made his maximum in the fourth frame of his eventual 6-3 win over Chinese compatriot Lei Peifan, just hours after Judd Trump and Neil Robertson had blasted the table conditions following Trump’s win over the Australian by the same score. Bingham then extended the evening’s drama by recovering from a 5-2 deficit to beat Welshman Williams, despite a howler at the start of the 10th frame of the match when he somehow contrived to pot the black from his own break-off shot. The Maximum Man! 💪 Zhang Anda completes the 208th professional 147. His third, and the sixth of the season. | — WST (@WeAreWST) Zhang, whose maximum was described as “perfect” by Eurosport commentator Ronnie O’Sullivan, will pocket at least a share of the tournament’s £15,000 highest break prize, eclipsing the 146 achieved by Zhao Xintong in the qualifying rounds. His brilliant break was in sharp contrast to the struggle faced by Trump in the opening stages of his clash with Robertson, a three-time UK winner who had battled through two rounds of qualifying after falling out of the world’s top 16. Trump belatedly found his form with consecutive breaks of 73, 126 and 67 helping him reel off five straight frames that kept alive his hopes of winning the prestigious title for the first time since 2011. Asked in his post-match interview if they were the worst conditions in which he had played, Trump said: “I’ve played in some bad conditions, but that was close. “It’s disappointing as it seems to be the bigger events. It was very heavy all the time. I’ve always struggled here because the tables are so heavy. “Hopefully they can change them. All the players have been struggling – hopefully they can do something about it.” Robertson, who made himself a heavy favourite to progress into the last 16 before a missed red on the cusp of extending his lead to 4-1 changed the course of the match, was equally scathing of the environment. “That was as tough as I’d ever played on,” said the Australian, a former three-time winner. “It was as unplayable as it gets in professional conditions. “Being such a tough sport anyway it can make either player look stupid.” Bingham’s early woe against Williams put even Trump’s travails into perspective as the 2015 world champion fashioned a top break of just 26 as he headed to the interval trailing 3-1. And despite falling further behind at 5-2, Bingham somehow managed to summon enough momentum to force a decider against the stuttering Williams, surviving even his break-off blunder before taking his first chance in the decider to book his place in the last 16. Earlier, veteran John Higgins rolled back the years as he completed a 6-0 whitewash of China’s He Guoqiang, who was making his Barbican debut. Scotsman Higgins, a four-time world champion, signalled his intent with early breaks of 110 and 92 before further extending his advantage into the interval. Two more half-century runs saw the 49-year-old comfortably into the last 16. “I am very pleased. The first two frames I knew it would be a tough game for him,” Higgins told BBC Sport. “It is a great atmosphere, I was nervous as well, but I got off to a decent start and I just put the pressure on him. “When I play like that, I feel like I am a match for anyone.”

The Pittsburgh Steelers take on what is typically an unenviable task -- traveling on a short week for a Thursday night primetime game. However, a few things are playing in Pittsburgh's favor as Week 12 of the NFL regular season kicks off. Namely, the "trip" to Cleveland is a little more than two hours by road and when the Steelers arrive there, they'll be facing a backup quarterback at the helm of a massively underwhelming 2-8 Browns team. The Steelers (8-2) are coming off a huge win over Baltimore to stay atop the AFC North. And Pittsburgh is beginning to set its sights on potential home-field advantage come playoff time. ODDS AND TRENDS The Steelers are a consensus 3.5-point favorite. That includes at BetRivers, where they have been backed by 80 percent of the spread-line money. Pittsburgh's -195 moneyline to simply win the game has been even more popular, drawing 95 percent of all money wagered. The Browns enter Thursday night having failed to cover the spread in nine of their past 12 games. Meanwhile, the Steelers have covered the spread in every game during their five-game win streak. The 37.0 total points line has seen the Over backed by 65 percent of the money and 70 percent of the total bets. Each of Cleveland's past eight November home games has gone under the total points line. PROP PICKS --Steelers WR George Pickens Over 50 Receiving Yards (-195 at DraftKings): Russell Wilson has thrown six touchdowns in the four games since he took over as the starting quarterback. Two of those have gone to Pickens, who has at least 74 receiving yards in each of those games. There is some concern that Pittsburgh gains a big early lead and turns to a run-heavy attack, but Wilson throws an excellent deep ball and that plays into Pickens' strength. This is the most popular player prop at the book. --Steelers RB Najee Harris Anytime TD (+100 at BetRivers): That potential for a run-heavy approach should benefit Harris, who found the sledding tough against Baltimore with 63 yards on the ground. He was also held out of the end zone for the second time in three games. Keep in mind that Cleveland has allowed only three touchdowns on the ground all season, but the Browns have allowed 12 through the air. Harris has a trio of scores on the ground and receiving through 10 games. KEY STAT The Browns have won the first quarter in five consecutive home games against the Steelers. THE NEWS The Steelers have certainly been locked in. They are currently riding a five-game winning streak, most recently edging the Baltimore Ravens 18-16 on Sunday. Chris Boswell booted six field goals against Baltimore, while Wilson completed 23 of 36 passes for 205 yards and an interception. Meanwhile, Cleveland continues to go through the wringer. The Browns ended up on the wrong end of a 35-14 blowout while facing the host New Orleans Saints on Sunday, marking their seventh loss in the past eight games. Cleveland now has to go up against one of the most unforgiving defenses in the league. Browns quarterback Jameis Winston is determined to direct a fundamentally sound performance against Pittsburgh, which allows the second-fewest points per game in the NFL (16.2). "It's precision passing. Getting the ball out on time. Elite operation and just doing our job. It's the simple things," Winston said. "This team (the Steelers) is not going to try and fool you. They're going to line up and say, 'Give us your best, we're going to give you our best.'" Winston threw for 395 yards and two touchdowns on 30-for-46 passing in the setback against New Orleans, with Jerry Jeudy hauling in six catches for 142 yards and a score. Star running back Nick Chubb continued to struggle since his return from a knee injury that cut his 2023 season short, finishing with 50 yards on 11 carries. INJURY REPORT The Browns could be without standout defensive end Myles Garrett, who missed practice on Tuesday because of a hip injury. Wide receiver Elijah Moore (shoulder), guard Joel Bitonio (pectoral) and cornerbacks Denzel Ward (ribs/ankle) and Greg Newsome II (shoulder) were among those limited during the session. Linebacker Alex Highsmith is dealing with an ankle issue and was ruled out by the Steelers along with cornerback Cory Trice Jr. (hamstring). THEY SAID IT Wilson is starting to feel like he might be part of something special, but he also doesn't want Pittsburgh to get ahead of itself. "I definitely think that we have a chance (to make a deep playoff run)," said Wilson, who has played in two Super Bowls. "I think the biggest thing for us is continuing to just take each week as the most important week of it all. "I think that it's not really even just the week, it's just the day, it's just the moments in between. I think the greatest teams, the greatest players, in any sport, especially the teams I've been on, is the moment -- it's never too far away. It's right here, right now. And you're just locked into that." PREDICTION Divisional road games on short weeks typically shape up as a daunting task. That's not the case for the Steelers, who will be hyper-focused to put this one out of reach early before enjoying 10 days ahead of a trip to Cleveland. With a second game against the Browns before a huge game at Philadelphia, this is not an under-manned opponent Pittsburgh will look past. --Steelers 27, Browns 19 --Field Level MediaWATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that Alise Reicin, MD, President and Chief Executive Officer, will present at the Piper Sandler 36 th Annual Healthcare Conference being held in New York on December 3-5, 2024. For more information regarding one-on-one meetings, please contact your Piper Sandler representative. The live webcast can also be accessed under “ Events & Presentations ” on the Investors section of the Tectonic website at www.tectonictx.com . Once the conference has concluded, a replay of the webcast will be available on the Company’s website for approximately 90 days. About Tectonic Tectonic is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its proprietary GEODeTM (GPCRs Engineered for Optimal Discovery) technology platform, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit www.tectonictx.com and follow on LinkedIn .

Drivers, college protesters on Jon Keller's list of Boston's 2024 turkeys

Imran Khan supporters pushed back by security forces

Known for their postgame hugs of each other , the goaltending tandem of Jeremy Swayman and Linus Ullmark became one of the best in the league over three seasons for the Boston Bruins. Unfortunately for the duo, with Swayman's emergence in the playoffs last season and Ullmark's pending free agency in 2025, Boston sent Ullmark to the Ottawa Senators in June for depth forward Mark Kastelic, backup goaltender Joonas Korpisalo and a first-round pick in 2024. However, things haven't gone to plan for the Senators (9-11-1) or Bruins (10-9-3) with their starting netminders this season. Swayman and Ullmark have struggled immensely, each sporting a save percentage below .890. Here is what has gone wrong for the netminders: Jeremy Swayman's holdout The Bruins, who host the Vancouver Canucks on Tuesday night, decided in the offseason that Swayman would be their full-time starter, but they still had to sign the restricted free agent to a new contract. Unfortunately for Boston, that didn't come easily. Swayman held out until Oct. 6, two days before the Bruins' opener against Florida. After missing all of training camp and preseason, Swayman struggled in his first regular-season game, stopping just 20 of 24 shots in a 6-4 win over the Montreal Canadiens. Swayman's struggles could be attributed to the lack of preseason games that would've allowed him to ease back into the swing of things. Too many games to handle? Although Ullmark won the Vezina Trophy as the league's best goaltender in 2022-23, he only started 48 games, the lowest number of games started for a Vezina Trophy winner in a non-shortened season. In the three seasons Swayman and Ullmark were teammates with the Briuns, Swayman played 122 games and Ullmark 130, a near-even split. After spending three seasons in a tandem, perhaps neither goalie was prepared for a full-time starter role. Typically, a starting goaltender plays 50 or more games during a regular season. For Ullmark, the 48 games he started for Boston in 2022-23 were a career high. What the analytics say In addition to their poor save percentages, analytics also show that Swayman and Ullmark aren't necessarily victims of poor team defense in front of them. Ottawa, which plays next at San Jose on Wednesday, and Boston are fifth and 14th in shots against per game, respectively. When it comes to goals saved above expected , Swayman is the eighth-worst goalie in the league with a -6.5 mark, while Ullmark is 10th worst with -5.7. Ullmark is even worse in five-versus-five situations, ranking last among goaltenders with an -8.6 5v5 goals saved above expected. Swayman sports a -0.9 figure. Additionally, when it comes to their value provided to their teams, both Ullmark and Swayman have a negative 5v5 Wins Above Replacement, per MoneyPuck . Ullmark's is a league worst -1.43 while Swayman's is a -0.15. Can they turn things around? With both teams sitting outside the playoff picture, they'll need their netminders to return to form to make it to the postseason. Swayman's November was an improvement from October, albeit slight (.890 save percentage to .884 save percentage in October). On the flip side, Ullmark's has played worse, going from .904 to just .864 save percentage. Given their play before this season, it's likely that both find their form. However, if Swayman and Ullmark don't bounce back soon, Boston could be out of the playoffs for the first time since 2016, and Ottawa will miss the playoffs for the eighth straight season.